Xarelto print ad puts Janssen in hot water

Share this article:
Xarelto print ad puts Janssen in hot water
Xarelto print ad puts Janssen in hot water

FDA advertising watchdogs have taken issue with a Janssen ad for blood thinner Xarelto. The agency's Office of Prescription Drug Promotion issued a June 6 untitled letter to outline the reasons for its displeasure with an ad the drug maker ran in the January/February issue of WebMD Magazine.

The bad-ad team says the ad's use of bold-face type and colorful text is used in such a way as to minimize the drug's risks, particularly because the facing page outlining the risk lacks the colorful text and boldfaced styling, making the two pages appear “unconnected to the efficacy claims,”according to the letter.

The advertisement does boldface the phrase “Please see accompanying Medication Guide on the following pages,” but OPDP says this is not sufficient.

OPDP said the ad also makes a misleading claim, asserting that "there are no dosage adjustments..." This conflicts with the PI's statement that dosage should be lowered for certain patients, OPDP wrote.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.